Arie Regev | Vice President, Medical Global Patient Safety
Lilly and Company

Arie Regev, Vice President, Medical Global Patient Safety, Lilly and Company

Arie Regev, MD, FAASLD Dr. Arie Regev is a gastroenterologist and hepatologist with more than 30 years of experience in the treatment and research of liver diseases. He is the Vice President of Medical Global Patient Safety at Eli Lilly and Company, and he heads Eli Lilly’s Safety Advisory Hub. In addition, Dr. Regev is the chair of Eli Lilly’s Liver Safety Committee, a role he has held for more than 15 years.   Dr. Regev is an associate professor of medicine at the division of gastroenterology and hepatology of Indiana University School of Medicine. He was the co-chair of the Council of International Organizations of Medical Sciences (CIOMS) working group on Drug Induced Liver Injury (DILI) and was the co-author of the CIOMS summary on DILI published in June 2020. Dr. Regev is the founding co-chair of the IQ-DILI initiative and is currently the co-chair of the Immunotherapy Working Group, Gene Therapy Working Group, and the Pediatrics Working Group. He is the author of more than 150 publications and book chapters in major scientific journals and books. Prior to joining Eli Lilly, Dr. Regev was an associate professor of medicine and director of the hepatology training program of the University of Miami School of Medicine.

back to speakers

Get Involved At Drug Safety Congress Americas

 

For Sponsorship and Exhibition opportunities

Semen Sen
semen.sen@terrapinn.com
t/ + 646-619-1793

 

 

To Speak


Gina McHugh
gina.mchugh@terrapinn.com
t/ +1 646 619 1775

 

 

Marketing & Press Opportunities


Kaylie Brogan
kaylie.brogan@terrapinn.com
t/ +1 646 619 1785